Regeneron Pharmaceuticals Aktie
WKN: 881535 / ISIN: US75886F1075
|
29.04.2026 12:53:55
|
Cognizant Updates FY26 Guidance
(RTTNews) - Cognizant (CTSH) said its 2026 adjusted operating margin guidance is increased to 16.0% to 16.2%, year-over-year expansion of 20 to 40 basis points compared to prior guidance of 10 to 30 basis points of expansion. Constant currency revenue growth guidance is unchanged at 4.0% to 6.5%. Full-year 2026 adjusted EPS is expected to be in the range of $5.63 to $5.77, growth of 7% to 9%. The company expects second quarter revenue to be $5.45 to $5.52 billion, growth of 3.8% to 5.3%, or 3.2% to 4.7% in constant currency.
First quarter net income was $662 million compared to $663 million, prior year. EPS was $1.39, increased 3.7% year-over-year. Adjusted EPS was $1.40 increased 13.8%. Adjusted Operating Margin was 15.6%, increased 10 basis points year-over-year. Revenue was $5.4 billion, up 5.8% from last year, or 3.9% in constant currency.
In pre-market trading on NasdaqGS, Cognizant shares are down 4.75 percent to $52.50.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Regeneron Pharmaceuticals Inc.
|
09.09.26 |
NASDAQ Composite Index-Wert Regeneron Pharmaceuticals-Aktie: So viel Gewinn hätte eine Investition in Regeneron Pharmaceuticals von vor einem Jahr abgeworfen (finanzen.at) | |
|
02.09.26 |
Mittwochshandel in New York: Anleger lassen NASDAQ 100 zum Ende des Mittwochshandels steigen (finanzen.at) | |
|
02.09.26 |
Mittwochshandel in New York: nachmittags Pluszeichen im NASDAQ 100 (finanzen.at) | |
|
02.09.26 |
NASDAQ Composite Index-Papier Regeneron Pharmaceuticals-Aktie: So viel Gewinn hätte ein Regeneron Pharmaceuticals-Investment von vor 10 Jahren abgeworfen (finanzen.at) | |
|
02.09.26 |
Mittwochshandel in New York: NASDAQ 100 fällt zum Start zurück (finanzen.at) | |
|
01.09.26 |
Dienstagshandel in New York: NASDAQ Composite verbucht letztendlich Abschläge (finanzen.at) | |
|
01.09.26 |
Schwacher Handel: NASDAQ 100 liegt letztendlich im Minus (finanzen.at) | |
|
01.09.26 |
Börse New York: NASDAQ 100 gibt am Dienstagnachmittag nach (finanzen.at) |
Analysen zu Regeneron Pharmaceuticals Inc.
Aktien in diesem Artikel
| Regeneron Pharmaceuticals Inc. | 684,70 | -0,25% |
|